Molecular Screening and Therapeutics (MoST) study
The MoST study uses the power of genomic technology to characterise molecular changes in a patient's cancer that may help to identify a targeted therapy
MoST has a number of different screening populations
Our program — covers all different types of cancers:
Pan cancer subprogram (MoST and AYA-MoST)
- for patients, including Adolescents and Young Adults (AYA), with pathologically-confirmed advanced or metastatic solid cancers of any histological type, either during or after their last line of effective therapy.
Lung cancer subprogram (ASPiRATION)
- for adults with newly diagnosed, pathologically-confirmed metastatic non-squamous non-small cell lung cancer (NSCLC), with sufficient and accessible tissue for molecular screening.
Leukaemia and lymphoma subprogram (MoST-LLy)
- for patients with advanced blood cancers without an established therapeutic option.
MoST has two stages
We use genomic profiling to analyse the molecular characteristics of a patient’s tumour, we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.
A team of experts review the molecular profile of the tumour with other clinical and patient information. A report is provided to the referring clinician.
Patients identified as possessing any of a range of molecular characteristics (identified during Stage 1) may be eligible to access treatment in a MoST therapeutic study (a clinical trial) or other targeted therapy.
Who can participate in MoST?
Pan cancer subprogram: Patients aged 16 years and older with an advanced and/or metastatic solid or blood cancer with limited treatment options, and who are willing and fit enough to participate in a clinical trial, are eligible.
Lung cancer subprogram: Patients aged 18 years and older with newly diagnosed metastatic non-squamous non-small cell lung cancer (NSCLC), who have not had any previous treatment for the lung cancer and who are willing and fit enough to participate in a clinical trial, are eligible.
Your treating oncologist will assess your eligibility, complete the MoST referral forms, and provide all relevant information.
What does participation involve?
- Discussing the study with the MoST team (either by telephone or face-to-face)
- Consenting to the access of samples held by pathology centres
- Consenting to the access of their medical records
- Donating a blood sample
- Completing questionnaires
- Providing optional consent for access to Medicare/PBS data